Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study

To improve clinical outcomes and shorten the vein-to-vein time of chimeric antigen receptor T (CAR-T) cells, we developed the FasT CAR-T (F-CAR-T) next-day manufacturing platform. We report the preclinical and first-in-human clinical studies evaluating the safety, feasibility, and preliminary effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Junfang, He, Jiaping, Zhang, Xian, Li, Jingjing, Wang, Zhenguang, Zhang, Yongliang, Qiu, Liyuan, Wu, Qionglu, Sun, Zhe, Ye, Xun, Yin, Wenjie, Cao, Wei, Shen, Lianjun, Sersch, Martina, Lu, Peihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262977/
https://www.ncbi.nlm.nih.gov/pubmed/35798714
http://dx.doi.org/10.1038/s41408-022-00694-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262977/
https://www.ncbi.nlm.nih.gov/pubmed/35798714
http://dx.doi.org/10.1038/s41408-022-00694-6

Ejemplares similares